ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Catalent, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022 GMT

SOMERSET, N.J.--(BUSINESS WIRE)--Jan 3, 2022--

Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene therapies, as well as consumer health products, today announced that members of its executive leadership team will virtually present at the 40th Annual J.P. Morgan Healthcare Conference at 7:30 a.m. ET on January 10, 2022.

A live webcast of the presentation will be accessible at http://investor.catalent.com and will be available for replay following the event.

About Catalent, Inc.

ADVERTISEMENT

Catalent, Inc. (NYSE: CTLT), an S&P 500 ® company, is the global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is the industry’s preferred partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,000 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply over 70 billion doses of nearly 7,000 products to over 1,000 customers annually. Catalent’s expert workforce exceeds 17,000, including more than 2,500 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated $4 billion in revenue in its 2021 fiscal year. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™

View source version on businesswire.com:https://www.businesswire.com/news/home/20220103005413/en/

CONTACT: Investor Contact:

Paul Surdez, Catalent, Inc.

(732) 537-6325

investors@catalent.com

KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY

INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH OTHER HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Catalent, Inc.

Copyright Business Wire 2022.

PUB: 01/03/2022 04:15 PM/DISC: 01/03/2022 04:17 PM

http://www.businesswire.com/news/home/20220103005413/en